A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.

Trial Profile

A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs AZD 5634 (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Jun 2017 Planned End Date changed from 11 Oct 2017 to 17 Oct 2017.
    • 05 Jun 2017 Planned primary completion date changed from 11 Oct 2017 to 17 Oct 2017.
    • 05 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top